内镜下套扎联合奥曲肽和埃索美拉唑治疗肝硬化并发食管静脉曲张破裂出血患者临床疗效研究*

doi:10.3969/j.issn.1672-5069.2024.06.026

摘要/Abstract

摘要： 目的探讨内镜下套扎术(EVL)联合奥曲肽和埃索美拉唑治疗肝硬化(LC)并发食管静脉曲张破裂出血(EVB)患者的临床效果。方法 2020年12月～2022年12月我院诊治的99例LC并发EVB患者,被随机分为对照组50例和观察组49例,均接受EVL和静脉注射埃索美拉唑治疗,观察组另给奥曲肽静脉泵入,治疗1 w,随访1 年。使用微量试剂盒检测血清一氧化氮(NO);采用ELISA法检测血清内皮素(ET)和血管紧张素Ⅱ(ATⅡ)水平;使用超声检测门静脉内径(PVD)、门静脉血流量(PVF)、脾静脉内径(SVD)和脾静脉血流量(SVF)。结果在急性期,观察组和对照组各死亡2例;在47例观察组和48例对照组生存者中,观察组24 h、48 h和72 h止血率分别为66.0%、95.7%和100.0%,与对照组的62.5%、85.4%和100.0%比,无显著性差异(P＞0.05);治疗后,观察组PVD、PVF和SVF分别为(10.5±1.6)mm、(252.4±42.6)mL/min和(526.3±68.9)mL/min,均显著低于对照组【分别为(12.1±1.4)mm、(304.5±41.6)mL/min和(611.4±64.5)mL/min,P＜0.05】;观察组血清NO水平为(73.2±7.6) mol/L,显著高于对照组【(64.9±7.4) mol/L,P＜0.05】,而血清ET和ATⅡ水平分别为(90.2±9.3)ng/L和(3.0±0.5)pg/mL,均显著低于对照组【分别为(104.8±11.4)ng/L和(4.1±0.6)pg/mL,P＜0.05】;术后随访1年,观察组和对照组再出血发生率分别为10.6%和12.5%(P＞0.05)。结论采用EVL联合奥曲肽和埃索美拉唑治疗LC并发EVB患者可以获得止血疗效,改善门脉血流动力学和血清血管活性指标,值得临床进一步观察。

关键词: 肝硬化, 食管静脉曲张破裂出血, 内镜下套扎, 奥曲肽, 埃索美拉唑, 治疗, 再出血

Abstract: Objective The aim of this study was to investigate clinical efficacy of endoscopic variceal ligation (EVL) and intravinous octreotide and esomeprazole infusion in the treatment of patients with liver cirrhosis (LC)and esophagogastric variceal bleeding(EVB). Methods 99 patients with LC and EVB were admitted to our hospital between December 2020 and December 2022, and were randomly divided into observation (n=49) and control group (n=50). All patients received EVL and intrvinous esomeprazole infusion, and those in the observation were additionally given intravenous octreotide bumping for 7 days. Serum nitric oxide (NO), endothelin (ET) and angiotensinⅡ (ATⅡ) levels were assayed. Portal vein diameter (PVD), portal vein flow (PVF), splenic vein diameter (SVD) and splenic vein flow (SVF) were detected by ultrasonography. Results Two and two patients didn’t survive emergent bleeding in both groups; of survivals, hemostasis rates at 24 h, 48 h and 72 h in the observation group were 66.0%, 95.7%and 100.0%, not significantly different compared to 62.5%, 85.4%and 100.0%(P＞0.05)in the control; after treatment, PVD, PVF and SVF in the observation were(10.5±1.6)mm,(252.4±42.6)mL/min and(526.3±68.9)mL/min, all significantly lower than [(12.1±1.4)mm, (304.5±41.6)mL/minand (611.4±64.5)mL/min, respectively, P＜0.05] in the control; serum NO level in the observation was (73.2±7.6) mol/L, much higher than [(64.9±7.4) mol/L, P＜0.05], while serum ET and ATⅡ levels were (90.2±9.3)ng/L and (3.0±0.5)pg/mL, much lower than [(104.8±11.4)ng/L and (4.1±0.6)pg/mL, P＜0.05] in the control group; one year of follow-up after treatment, re-bleeding rates in the observation and control groups were not much statistically significantly different (10.6%vs. 12.5%,P＞0.05). Conclusion EVL and octreotide and esomeprazole combination in dealing urgently with patients with EVB has a satisfactory hemostasis efficacy, which might improve liver hemodynamicsand serum vascular activity.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding, Endoscopic variceal ligation, Octreotide, Esomeprazole, Therapy, Re-bleeding

马莉, 顾中盛, 李想. 内镜下套扎联合奥曲肽和埃索美拉唑治疗肝硬化并发食管静脉曲张破裂出血患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 903-906.

Ma Li, Gu Zhongsheng, Li Xiang. Clinical efficacy of endoscopic variceal ligation and intravinous octreotide and esomeprazole infusion in the treatment of patients with liver cirrhosis and esophagogastric variceal bleeding[J]. Journal of Practical Hepatology, 2024, 27(6): 903-906.

参考文献

[1] Fouad TR, Abdelsameea E, Abdel-Razek W, et al. Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators. J Gastroenterol Hepatol, 2019,34(9):1604-1610.
[2] Liu W, Xu L, Xu F, et al. A retrospective analysis of the efficacy of endoscopic variceal ligation versus endoscopic tissue adhesive injection in the treatment of esophagogastric variceal bleeding. Dig Dis, 2023,41(3):468-475.
[3] Quintero J, Juampérez J, Mercadal-Hally M, et al. Endoscopic variceal ligation as primary prophylaxis for upper GI bleeding in children. Gastrointest Endosc, 2020,92(2):269-275.
[4] Zhang W, Wang Y, Chu J, et al. Investigation report on endoscopic management of esophagogastricvariceal bleeding by Chinese endoscopists. Medicine (Baltimore), 2022,101(42):e31263.
[5] Liu X, Guo X, Zhou H. Octreotide acetate combined with somatostatin upregulates miR-1291 and downregulates miR-331-3p in patients with cirrhosis and upper gastrointestinal bleeding. Am J Transl Res, 2021,13(8):9883-9891.
[6] Riha HM, Wilkinson R, Twilla J, et al. Octreotideadded to a proton pump inhibitor versus a proton pump inhibitor alone in nonvariceal upper-gastrointestinal bleeds. Ann Pharmacother, 2019,53(8):794-800.
[7] 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019版). 中华外科杂志,2019,57(12):885-892.
[8] Gralnek IM, Camus Duboc M, Garcia-Pagan JC, et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2022,54(11):1094-1120.
[9] Balcar L, Mandorfer M, Hernández-Gea V, et al, International variceal bleeding observational study group by the Baveno Cooperation: an EASL consortium. Predicting survival in patients with 'non-high-risk' acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding. J Hepatol, 2024,80(1):73-81.
[10] Sun XC, Yuan WF, Ma WJ, et al. Study on the preventive effect of intravenous esomeprazole in the management of nonvarices upper gastrointestinal bleeding. Medicine (Baltimore),2021,100(20):e25420.
[11] Abrishami M, Peymani P, Zare M, et al. Theeffect of octreotide in acute nonvariceal upper gastrointestinal bleeding: A randomized, double-blind, placebo-controlled trial. J Res Pharm Pract, 2020,9(2):94-100.
[12] Camilo SMP, Almeida ÉCS, Sousa JB, et al. Chronic use of proton pump inhibitors and the quantity of g, d, and ecl cells in the stomach. Arq Bras Cir Dig, 2020,33(2):e1506.
[13] Ruberto MF, Piras MS, SorbelloO, et al. Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk. Eur Rev Med Pharmacol Sci, 2021,25(17):5518-5524.
[14] Duan Y, Chen J, Cui H, et al. The effect of pantoprazole and somatostatin combined with thrombin in the treatment of non-esophagogastric varicosity upper gastrointestinal bleeding. Am J Transl Res, 2021,13(5):5484-5490.
[15] Li F, Wang T, Liang J, et al. Albuminbilirubin grade and INR for the prediction of esophagogastric variceal rebleeding after endoscopic treatment in cirrhosis. Exp Ther Med, 2023,26(5):501.
[16] Liu CH, Liu S, Zhao YB, et al. Development and validation of a nomogram for esophagogastric variceal bleeding in liver cirrhosis: A cohort study in 1099 cases. J Dig Dis, 2022,23(10):597-609.
[17] Song XJ, Liu JL, Jia SY, et al. Portal vein computed tomography imaging characteristics and their relationship with bleeding risk in patients with liver cirrhosis undergoing interventional therapy. World J Clin Cases, 2023,11(18):4277-4286.
[18] 詹致远,申洋,王凡冰. 内镜下套扎术联合奥美拉唑和奥曲肽治疗肝硬化并发食管静脉曲张首次出血患者短期疗效分析. 实用肝脏病杂志,2022,25(6):865-868.
[19] Darmadi D, Ruslie RH. Endothelin-1 level as a predictor of hepatopulmonary syndrome in liver cirrhosis. Med Glas (Zenica), 2020,17(2):389-394.
[20] 伍畅,张远安,彭春芬. 内镜下套扎术后应用卡维地洛治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究. 实用肝脏病杂志,2021,24(3):403-406.

内镜下套扎联合奥曲肽和埃索美拉唑治疗肝硬化并发食管静脉曲张破裂出血患者临床疗效研究^*

Clinical efficacy of endoscopic variceal ligation and intravinous octreotide and esomeprazole infusion in the treatment of patients with liver cirrhosis and esophagogastric variceal bleeding

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张少博, 张树庚, 刘连新. 免疫治疗肝细胞癌肝移植患者现状和前景展望^*[J]. 实用肝脏病杂志, 2024, 27(6): 801-803.
[2]	郑浩, 张树庚, 王嘉倍, 郭亚飞. 肝移植术治疗肝细胞癌患者肿瘤复发再治疗策略^*[J]. 实用肝脏病杂志, 2024, 27(6): 804-807.
[3]	朱泽斌, 张树庚, 刘连新. 靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 808-811.
[4]	张天挺, 许晶, 姜正伟, 嵇卉. 丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 820-823.
[5]	张丽, 冯禧轩, 刘飞, 延欢欢. 丙酚替诺福韦联合PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 824-827.
[6]	何振文, 徐刚, 孟华, 陈辉, 周庆坤. 艾米替诺福韦再治疗低病毒血症的慢性乙型肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 828-831.
[7]	朱中华, 胡均贤, 李炎. 索非布韦/达克拉韦治疗CHC患者血清血管性血友病因子和可溶性血管黏附因子1水平变化^*[J]. 实用肝脏病杂志, 2024, 27(6): 836-839.
[8]	张珂瓈, 童静, 李昌平. 接受达拉他韦和阿舒瑞韦治疗的初治基因1b型慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 840-843.
[9]	乔进, 赵彦, 窦志华. 半量索磷布韦联合全量达卡他韦治疗终末期肾病合并慢性丙型肝炎患者疗效和耐受性评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 844-847.
[10]	陈蓉蓉, 蒋黎黎, 曹利华. 自身免疫性肝炎患者血清细胞因子水平变化及其与治疗应答的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 852-855.
[11]	高宇, 杨磊, 胡光明, 孙占虎, 周涛, 肖杰. 自身免疫性肝炎患者血清巨噬细胞迁移抑制因子和白细胞介素-21水平变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 866-869.
[12]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[13]	董旭, 秦阳华, 廖威, 许明晓, 葛玲玲, 李成忠. 乙型肝炎肝硬化和慢加急性肝衰竭患者并发感染影响因素与预后分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 891-894.
[14]	魏唯, 初丽敏, 王超, 吴明, 平东兰, 池冰. 乙型肝炎肝硬化患者营养状况及肌少症发生率调查^*[J]. 实用肝脏病杂志, 2024, 27(6): 895-898.
[15]	陈思艳, 郭道宁, 邹晓攀, 漆家高. 彩色多普勒超声评估肝硬化门静脉高压症患者TIPS术后支架功能研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 899-902.